From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

Post-Transplant Pembrolizumab Consolidation Improves PFS in Relapsed/Refractory Hodgkin Lymphoma

In patients with high-risk, relapsed/refractory classical Hodgkin lymphoma (cHL) who have undergone autologous hematopoietic cell transplantation (AHCT), consolidation therapy with the PD-1 inhibitor pembrolizumab...
WIB_icon

New Study Supports “R2” Regimen in Previously Untreated Follicular Lymphoma

The combination of lenalidomide and rituximab, known as the R2 regimen, improved progression-free survival (PFS), time to next treatment (TTNT), and complete response (CR)...

Hematologic Malignancies Drive In-Hospital Death Rates

In the past 17 years, the overall rate of in-hospital deaths among patients with hematologic malignancies has decreased by 30 percent, with a corresponding...
WIB_icon

Higher Dose, Longer Duration of Eltrombopag Improves Likelihood of Response in Refractory Severe Aplastic...

The thrombopoietin receptor agonist eltrombopag was approved by the U.S. Food and Drug Administration for the treatment of adults with refractory severe aplastic anemia...
WIB_icon

Is “Watching and Waiting” Enough for Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma?

For patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), active surveillance appeared to be a feasible initial management strategy, according to an analysis published in...
WIB_icon

Evaluating Thalidomide-Cyclophosphamide-Prednisone for Idiopathic Multicentric Castleman Disease

An oral combination of thalidomide, cyclophosphamide, and prednisone (TCP) induced durable tumor and symptomatic response rates in nearly half of patients with newly diagnosed...
WIB_icon

Venetoclax Plus Obinutuzumab Confers High MRD-Negative Rates in CLL

Results from a phase Ib study demonstrated that the combination of the BCL2 inhibitor venetoclax with the anti-CD20 monoclonal antibody obinutuzumab was safe and...

Aggressive Imatinib Dose Escalation Shows No Improvement Over Standard Escalation in CML

For patients with newly diagnosed chronic myeloid leukemia (CML), aggressive dose escalation of imatinib failed to improve response and survival rates compared with a...
WIB_icon

Can a Virtual Benign Hematology Consult Improve Access to and Quality of Care?

A multidisciplinary team of researchers developed a virtual benign hematology consultative service that can potentially reduce the time it takes a specialist to examine...
WIB_icon

Carfilzomib Versus Bortezomib: Comparing Proteasome Inhibitors in Newly Diagnosed Myeloma

Carfilzomib plus melphalan and prednisone (KMP) failed to improve survival outcomes for patients with newly diagnosed multiple myeloma (MM) compared with bortezomib plus melphalan...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.